18FDG–PET–CT improves breast cancer staging

Published on December 17, 2012 at 5:15 PM · 2 Comments

By Lynda Williams, Senior medwireNews Reporter

A prospective study has shown fluorodeoxyglucose positron emission tomography/computed tomography (18FDG-PET-CT) to be a powerful tool for the detection of nodal and distant metastatic disease in patients with breast cancer.

When applied to 254 patients with stage II or III disease diagnosed by clinical examination, magnetic resonance imaging, or ultrasound, 18FDG-PET-CT findings led to a change of American Joint Committee on Cancer stage in 30.3% of patients, report David Groheux (Hôpital Saint-Louis, Paris, France) and co-authors.

18FDG-PET-CT had the greatest impact on patients with the most advanced disease, leading to a stage change in 16.1% of stage IIB patients, 31.7% of stage IIIA patients, 51.4% of stage IIIB patients, and 47.1% of stage IIIC patients.

"It is hoped that the information provided at initial staging might lead to better management of these patients who account for the largest mortality rate from breast cancer," say Groheux et al.

As 18FDG-PET-CT findings resulted in a stage change in just 4.5% of stage IIA patients, however, the team believes that the imaging technique may be "justified" only for patients with stage IIB disease or above.

Stage modification was prompted by the detection of previously unsuspected disease in the infraclavicular, supraclavicular, or internal mammary nodes, or distant metastases by 18FDG-PET-CT.

Following up patients with clinical IIB or greater disease, 3-year disease-specific survival was significantly shorter for the patients with distant metastases on 18FDG-PET-CT compared with those who had no evidence of distant metastases, at 57% versus 88%.

In multivariate analysis, distant metastatic disease on 18FDG-PET-CT and a triple-negative breast cancer phenotype were the only significant prognostic factors for disease-specific survival. The relative risk for death for M1 versus M0 patients was 26.60, while the relative risk for triple-negative phenotype versus other phenotypes was 18.58.

"The remarkable progression in the yield of 18FDG-PET-CT with advancing clinical stage and the correlation between PET-CT findings and prognosis are strong arguments that the overwhelming majority of patients classified as M+ on the basis of 18FDG-PET-CT have true-positive metastases," the researchers say.

Nevertheless, they emphasize that as their findings were in a single institution, the research must be repeated in other settings.

Licensed from medwireNews with permission from Springer Healthcare Ltd. ©Springer Healthcare Ltd. All rights reserved. Neither of these parties endorse or recommend any commercial products, services, or equipment.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
  1. saad zakko saad zakko United Kingdom says:

    Dear Sir,
      It is very interesting to see that PET/CT has such impact on the proper staging of breast cancer in stage II and III and this will lead to a more appropriate selection of mode of therapy.
      Most of surgeon do staging of breast cancer usually after surgery and then select the proper post-operative therapy. My question is now, is it time that we do the staging before surgery? If not , what are the points against it?
    Thanks,
    Dr SAAD ZAKKO
    szakko@gmail.com

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
New drug shows promise against treatment-resistant non-small cell lung cancer